Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Daratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfil...

Descripción completa

Detalles Bibliográficos
Autores: Moreau, Philippe, Chari, Ajai, Martínez-López, Joaquín, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, Rubia, Javier de la, Encinas, Cristina, Mateos, Maria Victoria, Salwender, Hans, Rodríguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, María, Goldschmidt, Hartmut
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/347169
Acceso en línea:http://hdl.handle.net/10261/347169
Access Level:acceso abierto
Palabra clave:Cancer therapy
Drug therapy
Descripción
Sumario:Daratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfilzomib is approved as monotherapy and in combination regimens, including daratumumab and dexamethasone (D-Kd), for RRMM [6]. In the phase 3 CANDOR study, D-Kd (intravenous [IV] daratumumab; carfilzomib 56 mg/m2 twice weekly) improved progression-free survival (PFS) versus Kd in the overall population and lenalidomide-refractory patients [7, 8]. In the phase 3 A.R.R.O.W. study, once-weekly carfilzomib (70 mg/m2) significantly prolonged PFS versus twice-weekly carfilzomib (27 mg/m2), providing a safe and more convenient Kd dosing regimen [9].

Similares en LA Referencia